Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

5.090 -0.040 (-0.78%)
Streaming Delayed Price Updated: 12:32 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
4 Analysts Assess Ardelyx: What You Need To Know
 
Via Benzinga
Ardelyx Q2 Revenue Jumps 33%
Via The Motley Fool
Topics Intellectual Property
Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming
Via Stocktwits
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Which stocks are moving after the closing bell on Monday?
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Earnings Scheduled For August 4, 2025
 
Via Benzinga
What to Expect from Ardelyx's Earnings
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
Breaking Down Ardelyx: 4 Analysts Share Their Views
 
Via Benzinga
Ardelyx Inc (NASDAQ:ARDX) Surges 11.6% After Q2 2025 Earnings and Revenue Beat Estimates
Ardelyx (ARDX) Q2 2025 earnings beat estimates with $97.7M revenue (+33% YoY) and -$0.08 EPS. Strong IBSRELA & XPHOZAH sales drove growth, sparking an 11.6% after-hours stock surge. 
Via Chartmill
Topics Earnings
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For February 20, 2025
 
Via Benzinga
What Analysts Are Saying About Ardelyx Stock
 
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Ardelyx Stock
 
Via Benzinga
Ardelyx Beats Q3 Sales Estimates, Shares Climb
Ardelyx reported its third-quarter results after Thursday's closing bell. Here's a look at the details from the report: 
Via Benzinga
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Ardelyx's Earnings Outlook
 
Via Benzinga
What 6 Analyst Ratings Have To Say About Ardelyx
 
Via Benzinga
Analyst Expectations For Ardelyx's Future
 
Via Benzinga
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism
Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah. 
Via Stocktwits
Ardelyx Tops Estimates as Sales Surge
The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah. 
Via The Motley Fool
Palantir Rally Loses Steam, Walmart Outlook Disappoints: What's Driving Markets Thursday?
Stocks tumbled Thursday, with all major indices in the red, one day after the S&P 500 notched another all-time high in Wednesday’s trading session. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Get Your Money Out of These 3 Biotech Stocks Before the End of July
These stocks are at a risk of providing negative returns to shareholders due to the several operational challenges faced by the companies. 
Via InvestorPlace
Ardelyx Files Lawsuit Over Medicare Drug Payment Rules, Claims It Will Limit Patient Access To Kidney Disease Treatment
Ardelyx challenges CMS in a lawsuit over Medicare's inclusion of Xphozah in bundled payments, affecting kidney disease drug accessibility. 
Via Benzinga
Topics Lawsuit
Why Ardelyx Stock Is Dropping
Ardelyx shares are trading lower Tuesday after the company announced it has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services End-Stage Renal Disease (ESRD)... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.